January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” This study evaluated the efficacy and safety of durvalumab combined with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy for 40 patients with resectable stage III Non-small Cell Lung Cancer (NSCLC). The treatment achieved a 65% Objective Response Rate (ORR), with 67.5% of patients achieving Major Pathological Response (MPR) and 22.5% achieving Complete Pathological Response (pCR). The expression of PD-1 on T lymphocytes significantly decreased post-treatment, indicating improved immune function. Common adverse events included hair loss (47.5%), nausea and vomiting (42.5%), and fatigue (40%), mostly grades 1 and 2. The average Disease-Free Survival (DFS) was 21.49 months, and Overall Survival (OS) was 24.79 months. The treatment showed a high pathological response rate and good tolerability, suggesting potential for extending patient survival.
October 2024 in “Journal of the Endocrine Society” Metastatic cervical cancer can cause rare, severe Cushing's syndrome with high risk of death.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
April 2024 in “Journal of pharmacy & pharmacognosy research” A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.
March 2024 in “PLoS medicine” Physical activity, height, and smoking affect prostate cancer risk.
December 2023 in “Frontiers in oncology” Older ovarian cancer patients live longer and tolerate weekly chemotherapy better than three-weekly treatments.
January 2023 in “European journal of gynaecological oncology” KRT17 may be a new target for endometrial cancer treatment because it helps cancer cells move and form new blood vessels.
July 2021 in “Plastic and reconstructive surgery. Global open” Radiation therapy in breast cancer patients changes gene expression related to DNA damage, fibroblast growth, and hair follicle development, which could help improve treatment for radiation-induced fibrosis.
June 2021 in “Research Square (Research Square)” Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.
January 2021 in “Journal of Cancer Therapy” Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
September 2020 in “Acta Scientific Cancer Biology” Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.
September 2018 in “Journal of Investigative Dermatology” Non-white organ transplant patients have worse skin cancer outcomes due to later diagnosis and treatment.
April 2018 in “Journal of Investigative Dermatology” Nonmelanoma skin cancers have higher levels of certain osteopontin variants than normal skin.
September 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Non-melanoma skin cancer in darker-skinned people can be misdiagnosed, so doctors need to be more aware to diagnose it correctly and early.
May 2017 in “Journal of The American Academy of Dermatology” 595 nm pulsed dye laser is a cost-effective treatment for nonmelanoma skin cancer with a low recurrence rate.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Applying the anti-cancer drug Bortezomib to skin can promote hair growth and increase hair proteins through the GATA-3 factor.
January 2016 in “Journal of clinical case reports” Docetaxel treatment for breast cancer can cause permanent hair loss.
September 2013 in “International journal of radiation oncology, biology, physics” High dose rate electronic brachytherapy is an effective and safe non-surgical treatment for nonmelanoma skin cancer with good cosmetic results after three years.
May 2012 in “Journal of Clinical Oncology” Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.
April 2012 in “The Journal of Urology” Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.
February 2012 in “Community oncology” Finasteride for hair loss may increase the risk of certain cancers and has side effects; better regulation and education on its use are needed.
Finasteride's effects on prostate cancer are not clear from this text.
October 2010 in “International Journal of Dermatology” An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.
August 2010 in “The Journal of urology/The journal of urology” Male pattern baldness may be linked to prostate cancer risk.
June 2007 in “Expert Review of Dermatology” Men and women may have different risks of getting skin cancer.
March 2007 in “Journal of Obstetrics and Gynaecology Canada” Birth control pills slightly increase the risk of breast cancer, especially if used before the first full-term pregnancy.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
September 2003 in “Journal of the Royal Society of Medicine” Understanding breast cancer requires considering both medical advancements and social influences.
190 citations,
July 2006 in “Experimental Dermatology” The hedgehog signalling pathway is key in skin development and basal cell carcinoma, offering insights for prevention and treatment.
116 citations,
May 1992 in “The American Journal of Medicine” Flutamide rarely causes liver toxicity in prostate cancer patients.